Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 3
1977 8
1978 3
1979 2
1980 1
1981 1
1982 10
1983 3
1984 2
1985 2
1986 5
1987 2
1988 3
1989 5
1990 4
1991 10
1992 20
1993 20
1994 20
1995 21
1996 32
1997 30
1998 37
1999 50
2000 56
2001 44
2002 58
2003 107
2004 121
2005 158
2006 184
2007 184
2008 196
2009 199
2010 205
2011 227
2012 266
2013 269
2014 263
2015 270
2016 245
2017 259
2018 249
2019 260
2020 256
2021 249
2022 235
2023 231
2024 230
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,765 results

Results by year

Filters applied: . Clear all
Page 1
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Balázs N, Bereczki D, Kovács T. Balázs N, et al. Ideggyogy Sz. 2021 Nov 30;74(11-12):379-387. doi: 10.18071/isz.74.0379. Ideggyogy Sz. 2021. PMID: 34856086 Free article. Review. English.
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately t …
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available …
Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.
Grant JE, Chesivoir E, Valle S, Ehsan D, Chamberlain SR. Grant JE, et al. Am J Psychiatry. 2023 May 1;180(5):348-356. doi: 10.1176/appi.ajp.20220737. Epub 2023 Feb 22. Am J Psychiatry. 2023. PMID: 36856701 Clinical Trial.
In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior. ...At study endpoint, 60.5% of participants in the memantine group were "much or very much imp …
In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing h …
The use of memantine in neuropsychiatric disorders: An overview.
Lu S, Nasrallah HA. Lu S, et al. Ann Clin Psychiatry. 2018 Aug;30(3):234-248. Ann Clin Psychiatry. 2018. PMID: 30028898 Review.
For schizophrenia, memantine has been reported to be consistently effective for negative symptoms only. The manic phase of bipolar disorder also appears to benefit from memantine. The depressive phase of bipolar disorder and major depressive disorder did not respond …
For schizophrenia, memantine has been reported to be consistently effective for negative symptoms only. The manic phase of bipolar di …
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Kishi T, et al. J Alzheimers Dis. 2017;60(2):401-425. doi: 10.3233/JAD-170424. J Alzheimers Dis. 2017. PMID: 28922160 Review.
BACKGROUND: The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive. OBJECTIVE: We performed an updated systematic review and meta-analysis of the efficacy/safety of memantine in AD. ...Effect size based on a random-effects model was eval …
BACKGROUND: The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive. OBJECTIVE: We performed an updated s …
Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
Buccellato FR, D'Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti D. Buccellato FR, et al. Int J Mol Sci. 2023 Sep 9;24(18):13900. doi: 10.3390/ijms241813900. Int J Mol Sci. 2023. PMID: 37762203 Free PMC article. Review.
Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, the best approaches for managing the disease seem to combine pharmacological and non-pharmacological the …
Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antag …
Amantadine and memantine: a comprehensive review for acquired brain injury.
Ma HM, Zafonte RD. Ma HM, et al. Brain Inj. 2020 Feb 23;34(3):299-315. doi: 10.1080/02699052.2020.1723697. Epub 2020 Feb 20. Brain Inj. 2020. PMID: 32078407 Review.
This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been treated with amantadine or memantine. Both amantadine and memantine are commonly used in the acute rehabilitation setting follow …
This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been tr …
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and aging societies worldwide. Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. ...C …
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and …
Memantine.
Jarvis B, Figgitt DP. Jarvis B, et al. Drugs Aging. 2003;20(6):465-76; discussion 477-8. doi: 10.2165/00002512-200320060-00005. Drugs Aging. 2003. PMID: 12710865 Review.
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast on/off receptor kinetics. ...Memantine 10 mg/day improved measures of dementia in care-dependent inpatients with Alzheimer's disease …
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast …
[Memantine].
Molinuevo JL. Molinuevo JL. Neurologia. 2003 Jun;18(5):255-61. Neurologia. 2003. PMID: 12768511 Review. Spanish.
N-methyl-D-aspartate (NMDA) receptor antagonists have very extensive therapeutic potential in several central nervous system disorders and can be used as neuroprotective treatment in chronic neurodegenerative diseases and as symptomatic treatment in other neurologic diseases as e …
N-methyl-D-aspartate (NMDA) receptor antagonists have very extensive therapeutic potential in several central nervous system disorders and c …
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L. Yu SP, et al. Mol Neurodegener. 2023 Jul 3;18(1):43. doi: 10.1186/s13024-023-00636-1. Mol Neurodegener. 2023. PMID: 37400870 Free PMC article. Review.
Thus, ischemic stroke and AD share an NMDAR- and Ca(2+)-mediated pathogenic mechanism that provides a common receptor target for preventive and possibly disease-modifying therapies. Memantine (MEM) preferentially blocks eNMDARs and was approved by the Federal Drug Administ …
Thus, ischemic stroke and AD share an NMDAR- and Ca(2+)-mediated pathogenic mechanism that provides a common receptor target for preventive …
4,765 results